Related Experiment Video
Updated: Jul 8, 2026
05:44
Rodent Inferior Vena Cava Venoplasty Balloon Model
Published on: May 24, 2024
[Progress in pathogenesis and therapy of vasculitis syndrome]
Tomoki Origuchi1, Kunihiro Ichinose, Mami Tamai
1Graduate School of Health Sciences, Nagasaki University.
Summary
Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis research has advanced understanding of pathogenesis and treatment. Combination therapies and biologics show promise, but careful monitoring for adverse effects is crucial.
Area of Science:
- Immunology
- Rheumatology
- Pathogenesis of Vasculitis
Background:
- Antineutrophil cytoplasmic autoantibody (ANCA) research has elucidated aspects of vasculitis syndrome.
- Proinflammatory cytokines, like tumor necrosis factor-alpha, induced by infections, can trigger ANCA binding to endothelial cells.
- Bacterial mimicry of granule peptide sequences may contribute to ANCA production, leading to vasculitis via endothelial cell damage.
Purpose of the Study:
- To review the pathogenesis of ANCA-associated vasculitis.
- To summarize optimized therapeutic strategies for ANCA-associated vasculitis.
Main Methods:
- Review of research on ANCA pathogenesis.
- Analysis of European Vasculitis Study Group (EUVAS) multicentric randomized clinical trials.
- Evaluation of evidence for biologic therapies.
Main Results:
- Cyclophosphamide-corticosteroid combination therapy is an optimized treatment for ANCA-associated vasculitis, as shown by EUVAS trials.
- Emerging evidence supports the efficacy of biologic agents in treating ANCA-associated vasculitis.
Conclusions:
- Understanding ANCA pathogenesis has led to improved treatment strategies.
- While effective, biologic therapies require careful management of severe adverse effects.
Related Concept Videos
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
01:21Cytotoxic Edema: Pathophysiology
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...